SkyePharma secures Sanofi deal for Flutiform
This article was originally published in Scrip
Executive Summary
SkyePharma has entered into an exclusive development, licence and marketing agreement with Sanofi, covering Mexico, Central and South America for Flutiform (fluticasone propionate plus formoterol fumarate), its lead product for the treatment of asthma.